Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Company Growth (employees)
Cytokinetics was founded in 1997 and is headquartered in South San Francisco, US
Cytokinetics Office Locations
Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave
Cytokinetics Data and Metrics
Cytokinetics Financial Metrics
Cytokinetics's revenue was reported to be $4.2 m in Q1, 2017
USD
Revenue (Q1, 2017) | 4.2 m |
Net income (Q1, 2017) | (25.9 m) |
EBIT (Q1, 2017) | (23.3 m) |
Market capitalization (21-Jul-2017) | 602.9 m |
Cash (31-Mar-2017) | 49.4 m |
Cytokinetics's current market capitalization is $602.9 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 30.6 m | 46.9 m | 28.7 m | 106.4 m |
Revenue growth, % | 53% | (39%) | 271% | |
R&D expense | 49.5 m | 59.9 m | ||
General and administrative expense | 15.1 m | 27.8 m | ||
Operating expense total | 64.5 m | 61.7 m | 66.1 m | 87.7 m |
EBIT | (33.9 m) | (14.8 m) | (37.4 m) | 18.7 m |
EBIT margin, % | (111%) | (31%) | (131%) | 18% |
Interest expense | 2.7 m | |||
Interest income | 177 k | 94 k | 464 k | |
Pre tax profit | (33.7 m) | (14.6 m) | (37.5 m) | 16.5 m |
Net Income | (33.7 m) | (14.6 m) | (37.5 m) | 16.5 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 7.8 m | 9.4 m | 4.4 m | 6.5 m | 7.9 m | 8.4 m | 5.8 m | 59 m | 4.2 m |
R&D expense | 11.7 m | 11.4 m | 9 m | 12.6 m | 11.6 m | 13.5 m | 9.7 m | 19.3 m | 19.3 m |
General and administrative expense | 4.5 m | 4 m | 4.4 m | 4.5 m | 5.3 m | 6.8 m | 7.1 m | 7.2 m | 8.1 m |
Operating expense total | 16.2 m | 15.4 m | 13.3 m | 17.1 m | 16.8 m | 20.4 m | 16.8 m | 26.6 m | 27.4 m |
EBIT | (8.4 m) | (6 m) | (8.9 m) | (10.6 m) | (8.9 m) | (12 m) | (11 m) | 32.5 m | (23.3 m) |
EBIT margin, % | (108%) | (64%) | (202%) | (162%) | (112%) | (142%) | (190%) | 55% | (560%) |
Interest expense | (714 k) | (3.1 m) | |||||||
Interest income | (501 k) | (600 k) | 111 k | 436 k | |||||
Pre tax profit | (8.4 m) | (6 m) | (8.9 m) | (10.6 m) | (8.8 m) | (12.5 m) | (11.6 m) | (25.9 m) | |
Net Income | (8.4 m) | (6 m) | (8.9 m) | (10.6 m) | (8.8 m) | (12.5 m) | (11.6 m) | 31.9 m | (25.9 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 20.2 m | 20.2 m | 65.1 m | 66.9 m |
Current Assets | 79.3 m | 131.1 m | 113.1 m | 158.6 m |
PP&E | 1.2 m | 1.6 m | 1.8 m | 3.6 m |
Total Assets | 83.2 m | 133 m | 115.2 m | 170.1 m |
Accounts Payable | 3.7 m | 1.4 m | 2.2 m | 4.2 m |
Total Debt | 29.9 m | |||
Current Liabilities | 26.7 m | 23.9 m | 31.6 m | 33.3 m |
Total Liabilities | 75.8 m | |||
Additional Paid-in Capital | 537 m | 589.3 m | 603.1 m | 612.5 m |
Retained Earnings | (482.6 m) | (497.2 m) | (534.7 m) | (518.3 m) |
Total Equity | 54.4 m | 92.1 m | 68.6 m | 94.4 m |
Debt to Equity Ratio | 0.3 x | |||
Debt to Assets Ratio | 0.2 x | |||
Financial Leverage | 1.5 x | 1.4 x | 1.7 x | 1.8 x |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 12.4 m | 12.9 m | 22.5 m | 24.8 m | 26 m | 42.3 m | 27.7 m | 30.3 m | 49.4 m |
Current Assets | 80.1 m | 81.5 m | 110.8 m | 107.9 m | 100.5 m | 106.1 m | 96.6 m | 148.2 m | 211 m |
PP&E | 1.5 m | 1.5 m | 1.6 m | 1.6 m | 1.5 m | 1.8 m | 1.7 m | 2 m | 3.5 m |
Total Assets | 96.1 m | 87.2 m | 122.2 m | 112.7 m | 102.2 m | 113.2 m | 106.2 m | 158.2 m | 265.4 m |
Accounts Payable | 985 k | 1.6 m | 1.4 m | 1.6 m | 1.9 m | 547 k | 2.8 m | 668 k | 3 m |
Current Liabilities | 16.9 m | 13 m | 25.4 m | 29.1 m | 30.1 m | 24.7 m | 26.3 m | 29.3 m | 36.8 m |
Additional Paid-in Capital | 578.4 m | 579.3 m | 590.2 m | 591.5 m | 592.8 m | 604.9 m | 607.3 m | 609.9 m | 639.5 m |
Retained Earnings | (499.7 m) | (505.7 m) | (506.1 m) | (516.7 m) | (525.5 m) | (547.2 m) | (558.8 m) | (526.9 m) | (544.2 m) |
Total Equity | 78.7 m | 73.6 m | 84.2 m | 74.9 m | 67.3 m | 57.9 m | 48.7 m | 83.3 m | 95.4 m |
Financial Leverage | 1.2 x | 1.2 x | 1.5 x | 1.5 x | 1.5 x | 2 x | 2.2 x | 1.9 x | 2.8 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (33.7 m) | (14.6 m) | (37.5 m) | 16.5 m |
Accounts Payable | 1.7 m | (2.2 m) | 755 k | 1.7 m |
Cash From Operating Activities | (7.7 m) | (44.8 m) | 4.9 m | 37 m |
Purchases of PP&E | (542 k) | (1.1 m) | (562 k) | (1.6 m) |
Cash From Investing Activities | (1.5 m) | (4 m) | 16.1 m | (52.1 m) |
Cash From Financing Activities | 14.5 m | 48.9 m | 23.9 m | 16.9 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (8.4 m) | (6 m) | (8.9 m) | (10.6 m) | (8.8 m) | (12.5 m) | (11.6 m) | 31.9 m | (25.9 m) |
Accounts Payable | 985 k | 1.6 m | 1.4 m | 1.6 m | 1.9 m | 547 k | 2.8 m | 668 k | 3 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 32.7 k |
Financial Leverage | 2.8 x |
